Tamtam Try Tamtam free
Aflac logo

Aflac account plan

Employee benefits insurance policies

At a glance

Aflac sells supplemental health and life insurance in Japan and the U.S., with FY2025 total revenues of $17.2 billion and 12,716 full-time employees.

Aflac Incorporated, based in Columbus, Georgia, sells supplemental health and life insurance that pays cash benefits when a policyholder gets sick or hurt, covering costs not reimbursed by primary coverage. It operates in Japan, where it is the largest insurer by cancer and medical policies in force, and in all 50 U.S. states, selling through agents, brokers, banks and alliance partners. FY2025 total revenues fell 9.3% to $17.2 billion on investment losses, net earnings were $3.6 billion and adjusted earnings $4.0 billion ($7.49 per diluted share). It had 12,716 full-time employees at end-2025. Daniel P. Amos is Chairman and CEO.

Business units

Strategic priorities

Japan sales growth
Promote Miraito, Tsumitasu and the Anshin Palette medical product; Amos expects 2026 Japan sales to exceed 2025, with nine-month sales up 3.0%.
U.S. growth platforms
Grow group life, absence and disability, consumer markets and dental and vision, which grew 15% in Q3 2026 with dental and vision up 67%.
Capital efficiency through reinsurance
Internal reinsurance target raised to up to 30% of FSA reserves; about 500 billion yen of cancer reserves ceded to Aflac Re Bermuda, releasing about $1 billion of capital over time.
Investment repositioning
$7 billion repositioned through switch trades in 2026, mostly JGBs, to capture higher yields.
Capital return
$2.8 billion of buybacks in nine months of 2026 and 44 consecutive years of dividend increases.

Latest results

In Q3 2026 total revenues fell to $3.3 billion from $4.7 billion because of $1.1 billion of net investment losses, largely from repositioning the portfolio, and net earnings fell to $303 million ($.61 per diluted share). Adjusted earnings were $1.2 billion, or $2.43 per diluted share, against $2.49. Aflac Japan pretax adjusted earnings fell 15.2% in yen and sales fell 4.0% to ¥18.8 billion against the Miraito launch baseline, while Aflac U.S. pretax adjusted earnings rose 31.5%. Aflac now expects 2026 benefit ratios slightly below 60%-63% in Japan and below 48%-52% in the U.S.

Investments and deals

Aflac Re cancer reinsurance
A new internal cancer reinsurance transaction with Aflac Re in Q3 2026, after one established in Q4 2024, plus an external reinsurance transaction in Q1 2026.
Portfolio switch trades
$4.8 billion repositioned by Q2 2026, expected to add over $50 million of run-rate net investment income, rising to $7 billion by Q3.
Share repurchases
$3.5 billion of buybacks in 2025 and $2.8 billion in the first nine months of 2026.
Product launches
Miraito cancer insurance (March 2025), Tsumitasu savings life (June 2024) and Anshin Palette medical insurance (December 2025).

Challenges and risks

Cyber incidents
The June 2025 U.S. incident involved personal information of approximately 22.65 million individuals, and a June 25, 2026 Aflac Japan incident paused direct mail and outbound calls.
Shrinking Japan premiums
Japan net earned premiums fell 2.0% in yen in Q3 2026 from reinsurance and paid-up policies; annualized premiums in force fell 2.2% to ¥1.16 trillion.
Yen and Japan concentration
Concentration in Japan and in JGBs, yen/dollar exposure and interest rates are key risks; the yen was 6.8% weaker in Q3 2026.
Group disability claims
Higher incurred group disability claims lifted the U.S. benefit ratio to 49.5% in Q2 2026.
Competition in U.S. supplemental lines
Major medical carriers are entering supplemental lines, bundling and discounting.

What leadership says

“reduce risk, improve balance sheet efficiency, and ultimately generate a higher ROE”

Max K. Brodén, Senior EVP and CFO · Q2 2026 CFO video update, August 2026

“the more we do, the harder it is to find additional opportunities”

Brad Dyslin, Global Chief Investment Officer · Q3 2026 earnings call, November 5, 2026

“long-term and deliberate succession planning”

Dan Amos, Chairman and CEO · Q3 2026 earnings call, November 5, 2026

Where a supplier can help

Cybersecurity and data protection
Tied to the cyber incidents challenge: two breaches in the U.S. and Japan raise the need for security, monitoring and incident response.
Benefits distribution technology
Tied to the U.S. growth platforms priority: group, dental and vision and consumer-markets growth relies on broker platforms, enrollment and digital lead generation.
Claims management for disability
Tied to the group disability claims challenge: claims analytics and absence management tools.
Japan marketing operations
Tied to the Japan sales growth priority: direct mail, outbound and agency channels that were paused after the Japan cyber incident.
Investment and reinsurance analytics
Tied to the capital efficiency and investment repositioning priorities: ALM, reinsurance and portfolio tools.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Aflac?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Aflac

What does Aflac do?

Aflac sells supplemental health and life insurance in Japan and the U.S., paying cash benefits for eligible claims to cover costs that primary coverage does not reimburse.

What is Aflac's revenue?

FY2025 total revenues were $17.2 billion; Q3 2026 total revenues were $3.3 billion.

How many employees does Aflac have?

12,716 full-time employees at end-2025, of whom 6,804 at Aflac Japan and 5,117 at Aflac U.S.

Who leads Aflac?

Daniel P. Amos is Chairman and CEO, Virgil R. Miller President of Aflac Incorporated and Max K. Brodén CFO; Shinsuke Morimoto and Fred Simard become presidents of Aflac Japan and Aflac U.S. from January 1.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)